A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics

202271 citationsJournal Articlegreen Open Access

Authors

Priya Kumthekar · Northwestern University

Michael J. Avram · Northwestern University

Andrew B. Lassman · NewYork–Presbyterian Hospital

Nancy U. Lin · Harvard University

Eudocia Q. Lee · Harvard University

Sean Grimm · Rush University Medical Center

Margaret Schwartz ·

Abstract

This study suggests promise for potentially improved outcomes of HER-positive LMD patients when treated with intrathecal trastuzumab while remaining safe and well-tolerated for patients.

Topics & Keywords

Brain Metastases and Treatment Lung Cancer Research Studies Glioma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neuro-Oncology

Volume 25, Issue 3, pp. 557-565

DOI: 10.1093/neuonc/noac195

Field-Weighted Citation Impact: 10.05